At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 305 enrolled
Drug / intervention
NDI-034858 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis
In Brief
A Phase 2 clinical trial evaluating NDI-034858 and Placebo for Psoriatic Arthritis. Completed, enrolled 305 participants across 56 sites in 4 countries.
Detailed Summary
This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active Psoriatic Arthritis (PsA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesCzechia, Germany, Poland, United States
CollaboratorsNimbus Lakshmi, Inc.
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartJan 2022
Primary CompletionMay 2023
Study CompletionJun 2023
TodayJul 2026
First PostedDec 10, 2021
Enrollment StartJan 6, 2022
Primary CompletionMay 4, 2023
Study CompletionJun 2, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.6 years ago
Interventions
NDI-034858drug
NDI-034858 oral capsule
Placeboother
NDI-034858-matching oral placebo capsule